CHRONIC HEART FAILURE (CHF)

CHRONIC HEART FAILURE (CHF)

What is Chronic Heart Failure (CHF)
 

Chronic heart failure is a clinical syndrome in which the heart is unable to provide adequate cardiac output at rest or during exertion. It develops as a result of myocardial damage and reduced myocardial contractility caused by various cardiac or systemic diseases.

Causes

The main underlying conditions leading to CHF include:

  • Myocardial infarction (ischemic injury)
  • Myocarditis
  • Endocarditis
  • Arterial hypertension
  • Cardiomyopathies
  • Valvular heart defects
  • Cardiac arrhythmias

Classification (by left ventricular ejection fraction – LVEF)

According to the European Society of Cardiology (ESC), CHF is classified into:

1.    HFrEF – Heart Failure with Reduced Ejection Fraction (LVEF < 40%)
2.    HFmrEF – Heart Failure with Mildly Reduced Ejection Fraction (LVEF 41–49%)
3.    HFpEF – Heart Failure with Preserved Ejection Fraction (LVEF ≥ 50%)

Main Symptoms

  • Dyspnea during physical exertion or at rest
  • Orthopnea (dyspnea when lying flat)
  • Peripheral edema (especially lower limbs)
  • Hepatomegaly (enlarged liver)
  • Pronounced fatigue, even with minimal exertion
  • Paroxysmal nocturnal dyspnea

Diagnostics

The following diagnostic methods are essential:

  • Echocardiography (EchoCG) – to assess ejection fraction and structural heart changes
  • Electrocardiography (ECG) – for detecting arrhythmias or ischemic changes
  • Blood tests for NT-proBNP or BNP – biomarkers of heart failure indicating cardiac overload
  • Chest X-ray – to assess cardiomegaly and pulmonary congestion
  • Coronary angiography – when ischemic heart disease is suspected

Modern Treatment Approaches

Treatment is tailored individually based on the CHF type and symptom severity.

a) Pharmacotherapy (typically lifelong):

  • ACE inhibitors or ARBs (angiotensin receptor blockers)
  • Beta-blockers
  • Mineralocorticoid receptor antagonists
  • Diuretics (if fluid retention is present)
  • SGLT2 inhibitors (sodium-glucose co-transporter 2 inhibitors)

b) Interventional methods (as indicated):

  • Implantable cardioverter-defibrillator (ICD)
  • Cardiac resynchronization therapy (CRT)
  • Surgical interventions (e.g., revascularization)

Possible Complications

  • Frequent hospitalizations
  • Cardiac arrhythmias
  • Thromboembolic events
  • Cardiogenic shock
  • Secondary multi-organ dysfunction (kidneys, liver)

Prevention

  • Blood pressure and glucose control
  • Weight management
  • Limiting salt and fluid intake
  • Regular physical activity (when compensated)
  • Cessation of smoking and alcohol
  • Early diagnosis and management of underlying conditions (e.g., hypertension, ischemic heart disease)

When to See a Doctor

  • New or worsening dyspnea, especially while lying flat
  • Development of edema (legs, ankles)
  • Unusual fatigue or decline in physical capacity
  • Rapid weight gain due to fluid retention
  • Irregular heart rhythm or palpitations
     

Cardiology Services at VitaMed Medical Center (Yerevan, Byureghavan, Charentsavan, Stepanavan)

Cardiologist home visit 20.000 AMD
Electrocardiography 4.000 AMD
Echocardiography 15.000 AMD
ECG monitoring 24-hour (Holter monitoring) 15.000 AMD
Daily blood pressure Monitoring (SMAD) 8.000 AMD
Initial consultation with a cardiologist with the appointment of treatment, including an electrocardiogram 15000 AMD
Initial consultation with a cardiologist without examination 12000 AMD
Third visit to a cardiologist in a month 5000 AMD
This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.